Technical Analysis for RARE - Ultragenyx Pharmaceutical Inc.

Grade Last Price % Change Price Change
F 101.71 2.37% 2.35
RARE closed up 2.37 percent on Friday, June 11, 2021, on 1.69 times normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Up
Historical RARE trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
MACD Bullish Signal Line Cross Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Multiple of Ten Bullish Other 0.00%
Inside Day Range Contraction 0.00%
Up 3 Days in a Row Strength 0.00%
20 DMA Resistance Bearish 2.37%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 2.37%
Pocket Pivot Bullish Swing Setup 2.37%
Multiple of Ten Bearish Other 2.37%
Older End-of-Day Signals for RARE ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Ultragenyx Pharmaceutical Inc. Description

Ultragenyx Pharmaceutical Inc., a development-stage biotechnology company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare diseases in the United States. It develops various biologics product candidates, including KRN23, a human monoclonal antibody to bind and reduce the biological activity of fibroblast growth factor to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia; recombinant human beta-glucuronidase, an intravenous enzyme replacement therapy for the treatment of mucopolysaccharidosis 7; and recombinant human protective protein cathepsin-A, an enzyme replacement therapy for galactosialidosis. The company is also developing a range of small-molecule product candidates comprising triheptanoin, a substrate replacement therapy for patients with fatty acid oxidation disorders, as well as for patients with glucose transporter type-1 deficiency syndrome; and oral formulation of sialic acid to treat hereditary inclusion body myopathy. It has license agreements with AAI Pharma Services Corp. and HIBM Research Group; and a collaboration and license agreement with Nobelpharma Co., Ltd. The company was founded in 2010 and is headquartered in Novato, California.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Pharmaceutical Industry Acid Pharmacy Monoclonal Antibody Rare Diseases Phosphate Glucose Fatty Acid Myopathy Fibroblast Growth Factor Transporter Ibm Enzyme Replacement Therapy Molecule Product Mucopolysaccharidosis Biologics Product Deficiency Syndrome Biologics Pharma Services Rare And Ultra Rare Diseases

Is RARE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 179.647
52 Week Low 69.0
Average Volume 396,955
200-Day Moving Average 116.13
50-Day Moving Average 106.26
20-Day Moving Average 102.32
10-Day Moving Average 97.02
Average True Range 5.06
ADX 16.06
+DI 22.78
-DI 20.37
Chandelier Exit (Long, 3 ATRs) 100.06
Chandelier Exit (Short, 3 ATRs) 107.23
Upper Bollinger Bands 114.82
Lower Bollinger Band 89.82
Percent B (%b) 0.48
BandWidth 24.43
MACD Line -3.42
MACD Signal Line -3.50
MACD Histogram 0.084
Fundamentals Value
Market Cap 6.73 Billion
Num Shares 66.2 Million
EPS -7.01
Price-to-Earnings (P/E) Ratio -14.51
Price-to-Sales 34.13
Price-to-Book 12.33
PEG Ratio -0.24
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 106.83
Resistance 3 (R3) 106.41 104.29 105.97
Resistance 2 (R2) 104.29 102.99 104.50 105.69
Resistance 1 (R1) 103.00 102.18 103.65 103.42 105.40
Pivot Point 100.88 100.88 101.20 101.09 100.88
Support 1 (S1) 99.59 99.58 100.24 100.01 98.02
Support 2 (S2) 97.47 98.77 97.68 97.73
Support 3 (S3) 96.18 97.47 97.45
Support 4 (S4) 96.60